Stockreport

Unveiling Royalty Pharma (RPRX) Q3 Outlook: Wall Street Estimates for Key Metrics [Yahoo! Finance]

Royalty Pharma plc - Class A Ordinary Shares  (RPRX) 
US:NASDAQ Investor Relations: ir.reprosrx.com/investor-relations
PDF Revenues are forecasted to be $710.89 million, representing a year-over-year increase of 11.6%. Over the past 30 days, the consensus EPS estimate for the quarter has b [Read more]